Athena Athena

X

Find the latest Drugs in Development and Pipeline Prospector News of Dong-A ST Co., Ltd..

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Dong-A ST Co., Ltd.
korearepublicofnew Flag
Country
Country
South Korea
Address
Address
64 Cheonhodaero Dongdaemun-gu, Seoul 130-823
Telephone
Telephone
+82 02 920 8114
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

DMB-3115 (ustekinumab) is a proposed biosimilar to Stelara being used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.


Lead Product(s): Ustekinumab

Therapeutic Area: Dermatology Product Name: DMB-3115

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 17, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

DMB-3115 (ustekinumab) and Stelara demonstrated therapeutic equivalence when looking at percent change from baseline in PASI (Psoriasis Area and Severity Index) at Week 8 and Week 12.


Lead Product(s): Ustekinumab

Therapeutic Area: Dermatology Product Name: DMB-3115

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 17, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

According to the agreement, Dong-A ST will license out the exclusive rights for the development and commercialization of DA-3880 (darbepoetin alfa). DA-3880 is an ARANESP/NESP biosimilar for the treatment of anemic patients with chronic renal failure.


Lead Product(s): Darbepoetin alfa

Therapeutic Area: Hematology Product Name: DA-3880

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Polifarma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement November 09, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the license agreement, NeuroBo has obtained an exclusive license to develop and commercialize DA-1241 (a novel GPR119 agonist) and DA-1726, which are currently being evaluated for the treatment of nonalcoholic steatohepatitis (NASH), obesity and type 2 diabetes.


Lead Product(s): DA-1241

Therapeutic Area: Endocrinology Product Name: DA-1241

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: NeuroBo Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement November 08, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, which promotes the release of key gut peptides GLP-1, GIP and PYY, which, in turn, play an important role in glucose metabolism, lipid metabolism and weight loss.


Lead Product(s): DA-1241

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: DA-1241

Highest Development Status: PreclinicalProduct Type: Small molecule

Recipient: NeuroBo Pharmaceuticals

Deal Size: $37.0 million Upfront Cash: $22.0 million

Deal Type: Licensing Agreement September 15, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

As part of the termination, both Dong-A ST and Beactica Therapeutics will gain exclusive global rights for further development and commercialization for different compounds series developed during the collaboration.


Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Small molecule

Recipient: Beactica

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Termination September 06, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

STP0404 also demonstrated consistent pharmacokinetics at various dose levels showing drug exposure increased less-proportionally with dose, and presented an elimination half-life can support once daily dosing regimen.


Lead Product(s): STP0404

Therapeutic Area: Infections and Infectious Diseases Product Name: STP0404

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 03, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY